Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001128381) titled 'A Phase 2a clinical research trial evaluating an investigational study drug (GlyphAgo/SPT-320) in adults with generalized anxiety disorder (GAD) and sleep disturbance' on Sept. 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Primary Sponsor: Seaport Therapeutics
Condition:
Generalized Anxiety Disorder with Insomnia Symptoms
Generalized Anxiety Disorder with Insomnia Symptoms
Mental Health - Anxiety
Mental Health - Other mental health disorders
Intervention:
This Phase 2a, randomized, double-blin...